VISTA 缺陷加速致命性小鼠狼疮性肾炎的发生
本研究将 VISTA 缺陷小鼠与经典狼疮模型 Sle1.Sle3 小鼠杂交,发现 Sle1.Sle3 VISTA-/- 小鼠的蛋白尿和肾小球肾炎出现更早、更重,伴脾 CD4+ T 细胞与髓系细胞活化增强及促炎因子、趋化因子和 IFN 调控基因显著升高,但自身抗体滴度未增加。结论提示 VISTA 缺失通过增强髓系与 T 细胞活化及细胞因子产生(包括强 IFNα 特征)加重小鼠 SLE,支持增强 VISTA 免疫抑制活性用于治疗人类狼疮的策略。
要点
- VISTA 遗传缺陷使 Sle1.Sle3 小鼠蛋白尿与肾小球肾炎更早出现且更严重。
- Sle1.Sle3 VISTA-/- 小鼠脾 CD4+ T 细胞与髓系细胞活化增强,但自身抗体滴度未升高。
- VISTA 缺失伴随 IFNα、IFNγ、TNF、IL-10、CXCL10 等促炎因子及 IFN 调控基因显著升高。
核心结论
- 首次证明小鼠 SLE 中 VISTA 缺失通过增强髓系与 T 细胞活化及细胞因子产生(包括强 IFNα 特征)加重疾病,支持增强 VISTA 免疫抑制活性治疗人类狼疮的策略。
研究设计与样本
- 将 VISTA 缺陷小鼠与 Sle1.Sle3 小鼠(经典 SLE 模型)杂交,构建 Sle1.Sle3 VISTA-/- 小鼠并与 Sle1.Sle3 及 C57BL/6 VISTA-/- 小鼠比较。
- 对 Sle1.Sle3 VISTA-/- 小鼠的脾细胞进行分析,评估 T 细胞与髓系细胞活化状态。
主要发现
- Sle1.Sle3 VISTA-/- 小鼠蛋白尿和肾小球肾炎较 Sle1.Sle3 与 C57BL/6 VISTA-/- 小鼠显著加速且更严重。
- Sle1.Sle3 VISTA-/- 小鼠脾 CD4+ T 细胞和髓系细胞群体活化增强。
- Sle1.Sle3 VISTA-/- 小鼠自身抗体滴度未见增加。
- Sle1.Sle3 VISTA-/- 小鼠中与 SLE 相关的促炎细胞因子、趋化因子和 IFN 调控基因显著增加,如 IFNα、IFNγ、TNF、IL-10、CXCL10。
临床怎么用
- 提示 VISTA 通路是自身免疫病治疗的潜在靶点,增强 VISTA 免疫抑制活性可能成为人类狼疮的治疗策略。
- 动物模型结论,尚不能直接转化为临床用药推荐。
局限性
- 证据来自小鼠 SLE 模型,非人类研究。
- 未报告自身抗体滴度增加,提示 VISTA 缺失加重疾病主要通过细胞活化与细胞因子途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The targeting of negative checkpoint regulators as a means of augmenting antitumor immune responses is now an increasingly used and remarkably effective approach to the treatment of several human malignancies. The negative checkpoint regulator VISTA (V-domain Ig-containing suppressor of T cell activation; also known as programmed death 1 homolog or as death domain 1α) suppresses T cell responses and regulates myeloid activities. We proposed that exploitation of the VISTA pathway is a novel strategy for the treatment of human autoimmune disease, and therefore we undertook this study to determine the impact of VISTA genetic deficiency on lupus development in a lupus-prone mouse strain. METHODS: To evaluate whether genetic deficiency of VISTA affects the development of lupus, we interbred VISTA-deficient mice with Sle1.Sle3 mice, a well-characterized model of systemic lupus erythematosus (SLE). RESULTS: We demonstrated that the development of proteinuria and glomerulonephritis in these mice, designated Sle1.Sle3 VISTA-/- mice, was greatly accelerated and more severe compared to that in Sle1.Sle3 and C57BL/6 VISTA-/- mice. Analysis of cells from Sle1.Sle3 VISTA-/- mice showed enhanced activation of splenic CD4+ T cells and myeloid cell populations. No increase in titers of autoantibodies was seen in Sle1.Sle3 VISTA-/- mice. Most striking was a significant increase in proinflammatory cytokines, chemokines, and interferon (IFN)-regulated genes associated with SLE, such as IFNα, IFNγ, tumor necrosis factor, interleukin-10, and CXCL10, in Sle1.Sle3 VISTA-/- mice. CONCLUSION: This study demonstrates for the first time that loss of VISTA in murine SLE exacerbates disease due to enhanced myeloid and T cell activation and cytokine production, including a robust IFNα signature, and supports a strategy of enhancement of the immunosuppressive activity of VISTA for the treatment of human lupus.
引用
- Ceeraz S, Sergent PA, Plummer SF, et al. VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis. Arthritis Rheumatol. 2017. PMID: 27992697. doi:10.1002/art.40020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。